Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   39799   clinical trials with a EudraCT protocol, of which   6533   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2006-001195-21
    Sponsor's Protocol Code Number:D1448C00015
    National Competent Authority:Estonia - SAM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2006-05-08
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedEstonia - SAM
    A.2EudraCT number2006-001195-21
    A.3Full title of the trial
    A Multicenter, Double-blind, Randomised, Parallel Group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Mono-therapy in the Treatment of Elderly Patients with Generalised Anxiety Disorder (CHROMIUM Study).
    A.3.2Name or abbreviated title of the trial where available
    CHROMIUM Study
    A.4.1Sponsor's protocol code numberD1448C00015
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstraZeneca AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSeroquel SR
    D.3.2Product code ZD5077
    D.3.4Pharmaceutical form Prolonged-release tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNQuetiapine Fumarate Sustained Release
    D.3.9.1CAS number 111974-72-2
    D.3.9.2Current sponsor codeZD5077
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Information not present in EudraCT
    D.3.11.8Extractive medicinal product Information not present in EudraCT
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCoated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Generalised Anxiety Disorder
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to evaluate the efficacy of quetiapine fumarate sustained release (hereafter referred to as quetiapine SR) versus placebo in the treatment of anxiety symptoms in patients with Generalised Anxiety Disorder (GAD), as assessed by the change from randomisation in the HAM A total score at Day 64.
    E.2.2Secondary objectives of the trial
    1.The efficacy of quetiapine SR versus placebo by evaluating the response rate in the treatment of anxiety symptoms in patients with GAD.
    2.The efficacy of quetiapine SR versus placebo on the health-related quality of life of patients with GAD.
    3.The efficacy of quetiapine SR versus placebo in the treatment of anxiety symptoms in patients with GAD.
    4.The efficacy of quetiapine SR versus placebo by evaluating the remission rate in the treatment of anxiety symptoms in patients with GAD.
    5.The efficacy of quetiapine SR versus placebo in the treatment of depressive symptom in patients with GAD.
    6.The efficacy of quetiapine SR versus placebo in improving somatic symptoms in the treatment of patients with GAD.
    7.The efficacy of quetiapine SR versus placebo in improving sleep quality in patients with GAD.
    8.If quetiapine SR improves satisfaction with medication in patients with GAD, compared with placebo.
    9.The safety and tolerability of quetiapine SR in patients with GAD.

    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1.Provision of written informed consent before initiation of any study related procedures
    2.Men and women aged 66 years or older
    3.A documented clinical diagnosis of GAD according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) criteria 300.02 as assessed by M.I.N.I.
    4.A HAM-A total score ≥20 with Item 1 (anxious mood) and Item 2 (tension) scores ≥2 at both enrolment and randomisation
    5.A CGI-S score ≥4 at both enrolment and randomisation
    6.Absence of current episode of major depression, defined as having a MADRS total score of ≤16 at both enrolment and randomisation
    7.Be able to understand and comply with the requirements of the study, as judged by the investigator
    8.Outpatient status and living in home environment at enrolment and randomisation
    E.4Principal exclusion criteria
    1.A Mini Mental State Examination (MMSE) score ≤25
    2.Patients meeting the DSM-IV Diagnostic Criteria for Dementia of the Alzheimer’s type; Diagnostic Criteria for Vascular Dementia; DSM-IV Diagnostic Criteria for Dementia Due to Other General Medical Conditions (e.g., head trauma, intracranial structural abnormality, etc); Practice Parameter for Mild Cognitive Impairment (Neurology 2001;56: 1133-1142); Diagnostic Criteria of The Consortium for Dementia with Lewy Bodies; and the Consensus Diagnostic Criteria for Frontotemporal Dementia
    3.Patients with a DSM-IV Axis I disorder other than GAD or simple phobia within 6 months of enrolment, which is considered clinically relevant as judged by the investigator.
    4.Patients with a DSM-IV Axis II disorder having a major impact on the current psychiatric status.
    5.Patients who, in the investigator’s judgement, pose a current serious suicidal or homicidal risk or have made a suicide attempt within 6 months prior to randomization or patients who have a MADRS Item 10 score ≥4.
    6.Patients treated with antihypertensive medications must be on a stable dose for at least 30 days prior to Visit 1.
    7.Substance or alcohol abuse or dependence,.
    8.Use of drugs that induce or inhibit the hepatic metabolising cytochrome P450 3A4 enzymes within 2 weeks prior to randomisation.
    9.Evidence of clinically relevant disease, e.g., renal or hepatic impairment, significant coronary artery disease, cerebrovascular disease, viral hepatitis B or C, acquired immunodeficiency syndrome (AIDS) as judged by the investigator.
    10.A clinical finding that is unstable or that, in the opinion of the investigator, would be negatively affected by the study medication or that would affect the study medication.
    11.Conditions that could affect absorption and metabolism of study medication (e.g., malabsorption syndrome, liver disease) as judged by the investigator.
    12.Significant hearing dysfunction, visual impairment, or communication disabilities that would interfere with the accurate assessment of the patient or impact the conduct of the study.
    13.A current diagnosis of cancer (except basal or squamous cell skin carcinoma), unless in remission for at least 5 years.
    14.Current or past diagnosis of stroke.
    15.History of seizure disorder, except febrile convulsions.
    16.Prior history of Neuroleptic Malignant Syndrome.
    17.Receipt of electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) fo treatment of depression within 90 days prior to randomisation, or the presence of a vagal nerve sti,ulator (VNS) device.
    18.Use of antipsychotic, mood stabiliser, or antidepressant drugs within 7 days before randomisation, or use of fluoxetine within 28 days before randomisation, or use of monamine oxidase inhibitors (MAO inhibitors), anxiolytics or hypnotics within 14 days before randomisation (with the exception of those allowed with restriction per protocol), or use of a depot antipsychotic injection within 2 dosing interval before randomisation.
    19.Patients unable to swallow oral medications whole or have difficulty swallowing.
    20.Patients who in the investigators opinion will require psychotherapy (other than supportive psychotherapy) during the study period, unless psychotherapy has been ongoing for a minimum of 3 months prior to randomisation.
    21.Patients with any diagnosis of a neurological condition, such as Parkinson’s disease, Huntington’s disease, essential tremor, multiple sclerosis, prior brain injury, space-occupying lesions, etc.
    22.A patient with diabetes mellitus
    23.Clinically significant deviation from the reference range in clinical laboratory test results as judged by the investigator.
    24.An absolute neutrophil count (ANC) of ≤1.5 x 109 /L
    25.A thyroid-stimulating hormone (TSH) concentration more than 10% above the upper limit of the normal range of the laboratory used for sample analysis at enrolment, whether or not the patient is being treated for hypothyroidism.
    26.ECG results considered being clinically significant as determined by the investigator based on assessment by a centrally located experienced cardiologist interpreting the ECG.
    27.An ECG with a QTcF of ≥500 msec at enrolment.
    28.Known history of intolerance or hypersensitivity to quetiapine or to any other component in the tablets.
    29.Known lack of response to quetiapine in the treatment of anxiety in a dosage of at least 50 mg per day for 4 weeks (at any time before study start), as judged by the investigator.
    30.Contraindications as detailed in the country-specific prescribing information for quetiapine.
    31.Involvement in the planning and conduct of the study (applies to all AZ staff, the investigational site staff and third-party vendors).
    32.Previous randomisation in the present study or any AZ-sponsored GAD study on quetiapine.
    33.Participation in another clinical study or compassionate use programme within 4 weeks of randomisation or longer in accordance with local requirements.

    E.5 End points
    E.5.1Primary end point(s)
    The primary objective of the study is to evaluate the efficacy of quetiapine fumarate sustained release (hereafter referred to as quetiapine SR) versus placebo in the treatment of anxiety symptoms in patients with Generalised Anxiety Disorder (GAD), as assessed by the change from randomisation in the HAM A total score at Day 64.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Information not present in EudraCT
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA14
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of study is defined as database lock, which is the time point after which no patient will be exposed to study related activities.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Information not present in EudraCT
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Information not present in EudraCT
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Information not present in EudraCT
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others Yes
    F.3.3.7.1Details of other specific vulnerable populations
    Elderly
    F.4 Planned number of subjects to be included
    F.4.1In the member state24
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 90
    F.4.2.2In the whole clinical trial 530
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2006-08-01
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2006-06-08
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2008-05-22
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA